Impact Biomedical (IBO) Revenue (2022 - 2026)

Impact Biomedical (IBO) posted Revenue of $7000.0 for Q1 2026, down 61.11% on a QoQ basis from $18000.0 in Q3 2025.

Impact Biomedical (IBO) Revenue (2022 - 2026) Analysis & Trends

Impact Biomedical's Revenue history runs 3 years deep, the most recent figure standing at $7000.0 for Q1 2026.

  • Quarterly Revenue changed N/A year-over-year to $7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32000.0 (changed N/A YoY) and the FY2022 annual result came in at $50000.0, changed N/A from the prior year.
  • Revenue was $7000.0 for Q1 2026 at Impact Biomedical, down from $18000.0 in the prior quarter.
  • Across five years, Revenue topped out at $50000.0 in Q2 2022 and bottomed at $7000.0 in Q2 2025.
  • A 3-year average of $20500.0 and a median of $12500.0 in 2025 frame the typical range for Revenue.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.51 Bn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 2.99 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 3.61 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 1.56 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Impact Biomedical 47.44 Mn 50.67 Mn - 7,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 7,000.00
Sep 30, 2025 18,000.00
Jun 30, 2025 7,000.00
Jun 30, 2022 50,000.00